Market Forecasting
Make Confident Commercial Decisions with Robust, Indication-Level Forecasts
Accurate forecasting is the backbone for investment planning, asset valuation, launch preparation, and portfolio strategy. Thelansis builds transparent, evidence-driven market forecasts rooted in epidemiology, treatment dynamics, competitive intelligence, and access constraints.
We evaluate markets using real-world parameters like patient flow, treatment sequencing, uptake behaviour, access barriers, and competitor timings to provide credible and actionable projections.
What We Do:
Our forecasting approach integrates epidemiology models with segmented patient flows, line-of-therapy mapping and treatment journey analysis, competitor launch timelines, pricing, reimbursement, and access dynamics
We model multiple scenarios to highlight:
- Base, optimistic, and conservative revenue trajectories
- Sensitivity to pricing, uptake, and access variations
- Competitive disruption impacts
- Country-specific adoption patterns and constraints
Launching a new therapy in the oncology space is one of the most complex and challenging in the pharma and biotech industries. With evolving treatment landscapes, shifting market dynamics, and diverse patient journeys across geographies, forecasting future uptake has never been straightforward. One of our valued clients, a leading pharmaceutical company, approached Thelansis to develop a comprehensive global forecast for one of its later-stage pipeline assets targeting relapse and refractory cases within the oncology treatment setting. The client’s objective was to understand how similar products had performed in similar treatment and comparable market settings to devise strategic plans for launch, pricing, and lifecycle management.
Learn more: The Analogue Advantage: A Smarter Way to derive the market uptake and New Product revenue Forecast
In 2024, a mid-size specialty pharma company approached Thelansis with a clear challenge: its hero product, a second-line therapy in a tightly contested market, was set to enter Loss of Exclusivity (LOE) in about 18 months. The drug accounted for 38% of the company’s global revenue, with the US and EU5 markets accounting for most of that.
Learn more: How Thelansis helped a Pharma company mitigate LOE impact through Forecast Modelling & Market Analytics
We Provide Answers to Critical Questions:
Every forecast is built to support strategic planning, resource allocation, and evidence-based decision-making.
What is the true commercial potential of our asset?
How will competitor entries reshape share and adoption curves?
Which patient segments or geographies offer the highest value?
Which assumptions introduce the greatest commercial risk?
Need customize support?
Thelansis also caters to your specific needs by providing customized reports that satisfy your organizational requirements. Get on-demand customization of the report’s scope to exactly meet your needs.